Jagsonpal Pharmaceuticals reported Q4 FY26 PAT growth of 31% YoY to ~INR9 crore on revenue of INR64 crore, marking a recovery after two muted quarters.
The board recommended a 200% dividend (including 75% special) and received approval for an INR40 crore buyback, returning over INR66 crore to shareholders.
Management reiterated guidance to grow at 1.5x the Indian Pharma Market (IPM) growth, citing Q4 MAT growth of 14.2% vs IPM's 10.5% driven by improved MR productivity.
The company maintains a strong cash position of over INR190 crore and a net working capital cycle of 11 days, with a focus on value-accretive inorganic opportunities.